ASAQ, the artesunate-amodiaquine fixed-dose combination, was the first treatment developed by DNDi in partnership with Sanofi, and is produced in Morocco. Developed as a non-patented product, the technology transfer for ASAQ to a second partner in Africa is a vital part of DNDi’s strategy to increase patient access to this treatment, according to the market demand forecast of 100 million treatments.
In 2010, DNDi, with support from a group of experts, assessed various potential partners in Africa in order to ensure that all criteria for a successful technology transfer were met. In  2011, an agreement was signed with a partner in Tanzania – Zenufa.

More on ASAQ